JERUSALEM, Jan. 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. is proud to announce the addition of Dr. Nir Barzilai to its established scientific board.
Dr. Barzilai is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine. He is currently an Associate Professor in the Department of Medicine, Molecular genetics and the Diabetes Research Center and is a member of the Divisions of Endocrinology and Geriatrics. He is also the Director of the Montefiore Hospital Diabetes Clinic.
He has spent over 20 years in assisting patients internationally and training in vast fields from Medicine, Geriatrics, Endocrinology and Molecular Genetics. Dr. Barzilai has contributed his efforts to fine institutions including the NIH, the Royal Free Hospital in London, Israel Institute of Technology Medical School, Baylor College, Hadassah Hospital, Yale University, Cornell University Medical College and at The Albert Einstein College of Medicine.
Dr. Barzilai will help Oramed in it’s pursuits toward success with his expertise and experience in the industry. CEO Nadav Kidron adds, “Dr. Barzilai combines in his high level work attributes of two very different worlds. He incorporates both academic research and the insight of a practitioner. His knowledge as an academically inclined practitioner can help Oramed tremendously in the upcoming development of new medicinal products.”
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals’ is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comwww.oramedpharma.com Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute “forward- looking statements”. Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that Dr. Barzilai can help Oramed tremendously in the upcoming development of new medicinal products; that we are currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and for other diseases. Factors which may significantly change or prevent our forward looking statements from fruition include that oral insulin gel capsules may not be suitable for our intended purposes ; we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; we may be unable to retain our employees or consultants, we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer to our most recent 10- KSB filed on Edgar.
Oramed Pharmaceuticals, Inc.
CONTACT: Vinisha Agnihotri of Oramed Pharmaceuticals, Inc.,+1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com/
